Alcon AG (NYSE: ALC) — Company Overview, News & Financial Data
Alcon specializes in eye care products and services, focusing on innovative solutions for vision correction and health.
Alcon AG
Alcon AG is a global eye care device company that develops, manufactures, and markets surgical and vision care products. Headquartered in Geneva, Switzerland, with major operational centers in Fort Worth, Texas, the company operates across two principal segments: Surgical and Vision Care. Its Surgical portfolio includes equipment, instrumentation, intraocular lenses, and disposable products used in cataract, vitreoretinal, and refractive procedures. Its Vision Care portfolio encompasses contact lenses, contact lens care products, and ocular health eye drops. The company serves patients and eye care professionals across more than 140 countries through a worldwide commercial, manufacturing, and distribution infrastructure.
Snapshot
Operations
Products and/or services of Alcon AG
- Surgical Implantables: Intraocular lenses inserted during cataract surgery, including monofocal, advanced technology, and toric designs that correct presbyopia and astigmatism, providing permanent visual restoration for patients undergoing ophthalmic procedures worldwide.
- Surgical Consumables: Dedicated custom packs, viscoelastic materials, precision blades, cassette tubing, and single-use surgical accessories manufactured to support anterior and posterior segment ophthalmic procedures across hospitals and ambulatory surgery centers globally.
- Surgical Equipment: Advanced surgical consoles, femtosecond and refractive lasers, diagnostic visualization microscopes, and digital guidance systems designed for performing complex cataract, vitreoretinal, and refractive laser operations in clinical environments.
- Vision Care Contact Lenses: Daily disposable, monthly replaceable, and cosmetic contact lenses available in spherical, toric, and multifocal designs to correct myopia, hyperopia, astigmatism, and presbyopia across international consumer markets.
- Ocular Health Products: Over-the-counter lubricant eye drops, artificial tear formulations, and eyelid hygiene solutions produced to alleviate dry eye disease symptoms, improve tear film stability, and enhance ocular surface comfort.
- Contact Lens Care Solutions: Multipurpose cleaning fluids, hydrogen peroxide-based care systems, and daily rewetting drops engineered for the cleaning, disinfection, protein removal, and hydration of reusable contact lens products.
Alcon AG executive team
- David J. EndicottCEO & Director
- Timothy C. StonesiferSenior VP & CFO
- Ian BellSenior VP & COO
- Margaret BuckleyChief Accounting Officer
- Franck LeveillerSVP of Global Research & Development and Chief Scientific Officer
- Muru MurugappanSenior VP and Chief Information & Transformation Officer
- Daniel CravensVice President of Investor Relations
- Royce R. BedwardSenior VP, General Counsel & Corporate Secretary
- Kimberly MartinSenior VP and Chief HR & Corporate Communications
- Leon Sergio Duplan FraustroSenior VP & President of Americas
Latest news about Alcon AG
Dividend history
Dividends per share paid by Alcon AG, by financial year.
| Financial year | Interim | Final | Special | Total |
|---|---|---|---|---|
| FY2025 | — | $0.3584 | — | $0.3584 |
| FY2024 | — | $0.3334 | — | $0.3334 |
| FY2023 | — | $0.2640 | — | $0.2640 |
| FY2022 | — | $0.2360 | — | $0.2360 |
| FY2021 | — | $0.2050 | — | $0.2050 |
Key financials
Reported results for Alcon AG, in USD.
- Market cap
- 35B
- Revenue (TTM)
- 10.9B
- P/E ratio
- 54.8
- EPS (diluted, TTM)
- 1.3
- Dividend yield
- 0.5%
- Profit margin
- 5.9%
| Fiscal year end | Revenue | Operating income | Net income |
|---|---|---|---|
| 10.4B | 1.4B | 980M | |
| 9.9B | 1.4B | 1B | |
| 9.5B | 1B | 974M | |
| 8.7B | 672M | 335M |